This article has an addendum: Signed HIPPA forms from the parents of the 2 patients who were alive at the time of manuscript submission were obtained.
Original article: Oncotarget. 2019; 10:551–557. 551-557. https://doi.org/10.18632/oncotarget.26560
. 2023 May 19;14:502. doi: 10.18632/oncotarget.28445
Addendum: Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy
Stephanie A Toll
1,2,*,✉, Hung N Tran
3,*, Jennifer Cotter
2,4, Alexander R Judkins
2,4, Benita Tamrazi
2,5, Jaclyn A Biegel
2,4, Girish Dhall
1,2, Nathan J Robison
1,2, Kaaren Waters
1, Palak Patel
2, Robert Cooper
3,*, Ashley S Margol
1,2,*
Stephanie A Toll
1Division of Hematology, Oncology and Blood and Marrow Transplantation, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, Los Angeles, CA, USA
2University of Southern California Keck School of Medicine, Los Angeles, CA, USA
*These authors have contributed equally to this work
Find articles by Stephanie A Toll
Hung N Tran
3Kaiser Permanente Southern California, Los Angeles, CA, USA
*These authors have contributed equally to this work
Find articles by Hung N Tran
Jennifer Cotter
2University of Southern California Keck School of Medicine, Los Angeles, CA, USA
4Department of Pathology and Laboratory Medicine, Children’s Hospital Los Angeles, Los Angeles, CA, USA
Find articles by Jennifer Cotter
Alexander R Judkins
2University of Southern California Keck School of Medicine, Los Angeles, CA, USA
4Department of Pathology and Laboratory Medicine, Children’s Hospital Los Angeles, Los Angeles, CA, USA
Find articles by Alexander R Judkins
Benita Tamrazi
2University of Southern California Keck School of Medicine, Los Angeles, CA, USA
5Department of Radiology and Imaging, Children’s Hospital Los Angeles, Los Angeles, CA, USA
Find articles by Benita Tamrazi
Jaclyn A Biegel
2University of Southern California Keck School of Medicine, Los Angeles, CA, USA
4Department of Pathology and Laboratory Medicine, Children’s Hospital Los Angeles, Los Angeles, CA, USA
Find articles by Jaclyn A Biegel
Girish Dhall
1Division of Hematology, Oncology and Blood and Marrow Transplantation, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, Los Angeles, CA, USA
2University of Southern California Keck School of Medicine, Los Angeles, CA, USA
Find articles by Girish Dhall
Nathan J Robison
1Division of Hematology, Oncology and Blood and Marrow Transplantation, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, Los Angeles, CA, USA
2University of Southern California Keck School of Medicine, Los Angeles, CA, USA
Find articles by Nathan J Robison
Kaaren Waters
1Division of Hematology, Oncology and Blood and Marrow Transplantation, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, Los Angeles, CA, USA
Find articles by Kaaren Waters
Palak Patel
2University of Southern California Keck School of Medicine, Los Angeles, CA, USA
Find articles by Palak Patel
Robert Cooper
3Kaiser Permanente Southern California, Los Angeles, CA, USA
*These authors have contributed equally to this work
Find articles by Robert Cooper
Ashley S Margol
1Division of Hematology, Oncology and Blood and Marrow Transplantation, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, Los Angeles, CA, USA
2University of Southern California Keck School of Medicine, Los Angeles, CA, USA
*These authors have contributed equally to this work
Find articles by Ashley S Margol
1Division of Hematology, Oncology and Blood and Marrow Transplantation, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, Los Angeles, CA, USA
2University of Southern California Keck School of Medicine, Los Angeles, CA, USA
3Kaiser Permanente Southern California, Los Angeles, CA, USA
4Department of Pathology and Laboratory Medicine, Children’s Hospital Los Angeles, Los Angeles, CA, USA
5Department of Radiology and Imaging, Children’s Hospital Los Angeles, Los Angeles, CA, USA
*These authors have contributed equally to this work
✉
Correspondence to: Stephanie A. Toll, email : stoll@chla.usc.edu
Collection date 2023.
Copyright: © 2023 Toll et al.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PMCID: PMC10197959 PMID: 37204254
See "Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy" in volume 10 on page 551.